Mylan, Amgen score unanimous AdComm backing for Roche copycats; Alder raises $161M

Mylan and Amgen breezed through their advisory committee reviews on Thursday without any unexpected kickbacks for their two new knockoffs of a pair of Roche megablockbusters. Both won nods in unanimous votes, which is what you’d expect for drugs given a clean assessment by FDA insiders. Mylan was up with MYL-1401O, a biosimilar of Herceptin. Amgen, meanwhile, won applause for its copycat of Avastin.

CS Bio wants to build a new HQ building on the bayfront in Menlo Park, CA, according to a report in the San Jose Mercury News. The company says it plans to triple its work force in the next five years to about 300.

Alder BioPharmaceuticals $ALDR has raised $161 million as it preps for a BLA on its CGRP migraine therapy. The Bothell, WA-based biotech is building a commercial organization for their drug, which looks like it will compete against a range of rivals in the field.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->